DiscoveRx acquires the KINOMEscan kinase screening services division from Ambit Biosciences

DiscoveRx® Corporation announced today the acquisition of KINOMEscan kinase screening services division from San Diego-based Ambit Biosciences. The addition of this new business unit will further strengthen DiscoveRx’s position as the market leader of novel, proprietary and validated GPCR and kinase assays for high-throughput screening and profiling and will enable customers to improve research productivity and effectiveness, thus accelerating the discovery and development of new drugs. By combining solutions the new DiscoveRx offers the largest collection of assays comprising of over 400 functional cell-based GPCR and kinase assays as well as an industry leading panel of 442 kinase assays, thereby creating centers of excellence for both GPCRs and kinases.

“The acquisition of KINOMEscan represents our commitment to build a company and a brand that positions us as the leading solution provider across the drug discovery continuum. We are a leader in next generation GPCR and kinase technology with our award winning PathHunter® and HitHunter® brands. With the majority of pharmaceutical drug discovery programs centered around the GPCR and kinase target classes, the addition of the KINOMEscan platform, a proven technology for high-throughput kinase screening and profiling complements our PathHunter and HitHunter cell-based kinase and GPCR assay platforms. We are also excited about San Diego emerging as a center of excellence for kinase-based discovery technologies and services. Our new geography strengthens our ability to leverage the outstanding resources that exist at all of our locations,” said Pyare Khanna, Ph.D., Chief Executive Officer & President of DiscoveRx Corporation.